Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.47 |
| ▸ | AHCY | P23526 | 2/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799630 | 1.00 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL5319686 | 1.00 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL5318875 | 1.00 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL23776534 | 0.90 | AHCY (0.47) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL18512602 | 0.90 | AHCY (0.47) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL5370706 | 0.89 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL23776486 | 0.89 | PI4KA (0.42) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL12779230 | 0.87 | RXFP1 (0.40) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL22883255 | 0.87 | AHCY (0.64) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL31756651 | 0.87 | AHCY (0.64) | PI4KAPI4K2BPI4K2API4KBAHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENIUM PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARM INC (US) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | PI4KA 1455/4885PI4K2B 2027/4885PI4K2A 1655/4885 |
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | PI4KA 1455/4885PI4K2B 2027/4885PI4K2A 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.